Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 0.57 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119465 | 0.94 | KIF11 (0.56) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5110211 | 0.90 | KIF11 (0.56) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5112536 | 0.87 | KIF11 (0.51) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5112356 | 0.86 | KIF11 (0.51) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5114295 | 0.85 | KIF11 (0.51) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5112407 | 0.85 | KIF11 (0.78) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5119063 | 0.85 | KIF11 (0.52) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4363091 | 0.84 | KIF11 (0.57) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5108672 | 0.84 | KIF11 (0.51) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5113443 | 0.82 | KIF11 (0.60) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | claimed |
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060111374-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111374-A1 | Compounds, compositions, and methods | ALPP, MKI67, PCNA | KIF11 427/4885MAP1LC3B 1604/4885CYP3A4 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.